Application of 5-Aminosalicylic Acid Preparations in the Treatment of Inflammatory Bowel Diseases

Main Article Content

Yu.M. Stepanov
M.V. Stoykevich
O.V. Sorochan


The article is devoted to the comparative characterization of different derivatives of 5-aminosalicylic acid. Researches of the past decades have changed the presentation of the potential use of aminosalicylates in the therapy of various inflammatory bowel diseases. In connection with unknown etiology of Crohn’s disease and ulcerative colitis, there is no causal treatment of these diseases. The essence of treatment is reduced to inhibition of inflammatory activity during exacerbations and a course of preventive treatment. Numerous studies over the past 20 years have shown that the basis of basic treatment for nonspecific chronic inflammatory bowel diseases is 5-aminosalicylic acid drugs, or salicylates. When choosing the dosage form, you should take into account the differences between mesalazine preparations depending on the type of the coat. It is shown that in terms of pharmacokinetics, the most effective mesalazine dosage forms for the treatment of ulcerative colitis and Crohn’s disease with lesions of the colon are enteric coated tablets that provides a pH-dependent gradual release of 5-aminosalicylic acid throughout the entire colon. 5-aminosalicylic acid drugs available today on the pharmaceutical market are able to control the course of ulcerative colitis and Crohn’s disease with lesions of the colon in the majority of patients. The use of 5-aminosalicylic acid preparations is not limited to the treatment of ulcerative colitis and Crohn’s disease. The drug is widely used in other diseases of the bowel, such as diverticular disease of the colon, colitis banal, radiation damages of the colon, as well as to treat common diseases, such as irritable bowel syndrome. The study, which was conducted in the department bowel disease of the State Institution «Institute of Gastroenterology» for 2 years, showed a positive effect of 20-day treatment with Mesacol in uncomplicated diverticular disease. The use of Mesacol at a dose of 1,600 mg per day resulted in complete relief of abdominal symptoms in 68.7 % of patients.

Article Details

How to Cite
Stepanov, Y., Stoykevich, M., & Sorochan, O. (2016). Application of 5-Aminosalicylic Acid Preparations in the Treatment of Inflammatory Bowel Diseases. GASTROENTEROLOGY, (3.61), 80–87.
Reviews and Lections


Kushnir I. E. Vnekishechnyie proyavleniya hronicheskih vospalitelnyih zabolevaniy kishechnika [Extraintestinal manifestations of chronic inflammatory bowel disease]. Zdorovye Ukrainyi, 2007, no. 7, pp. 64-67. (In Russian).

Vorobyeva G. I., Halifa I. L. Nespetsificheskie Vospalitelnyie Zabolevaniya Kishechnika (Inflammatory Bowel Disease) Moscow, OOO "Miklosh", Publ., 2008. 400 р. (In Russian).

Rumyantsev V. G. Bolezni tolstoy kishki i anorektalnoy oblasti (Diseases Of The Colon And Anorectal Area) Moscow, OOO "Anaharsis", Publ., 2007. 224 р. (In Russian).

Malahinova N. A. Klinicheskiye osobennosti techeniya nespetsificheskogo yazvennogo kolita i bolezni Krona u detey [Clinical features of the course of ulcerative colitis and Crohn's disease]. Saratovskiy nauchno-meditsinskiy zhurnal, 2010. no. 3, pp. 650-653. (In Russian).

Lakatos L., Lakatos P. Changes in the epidemiology of inflammatory bowel disease Orv. Hetil., 2007, no. 4,Vol. 148 (5), pp. 223-228.

Wolters F. L. Russel M.G., Sijbrandij J. Disease outcome of inflammatory bowel disease patients: general outline of a Europe-wide population-dased 10-year clinical follow-up study. Scand. J. Gastroenterol. Suppl., 2006, Vol. 243, pp. 46-54.

Grigoreva G. A., Meshalkina N. Yu. Bolezn Krona (Crohn's Disease) Moscow, OOO "Medicina", Publ., 2007. 184 р. (In Russian).

Brar H., Einarson А. Effects and treatment of inflammatory bowel disease during pregnancy. Can. Fam. Physician, 2008, Vol. 54, , no. 7, рр. 981-983.

Baumgart D. C., Sandborn W.J. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet, 2007, Vol. 369, рр. 1641-1657.

Boyko T. Y., Simonova O. V. Nespetsifichniy virazkoviy kolit: standarti diagnostiki i likuvannya: metodichni rekomendatsii (Ulcerative Colitis Diagnostic Standards And Treatment Methodic Recommendations) Kiev, Publ., 2009. 43 p. (In Ukrain).

Belousova E. A. Evropeyskiy konsensus po lecheniyu bolezni Krona [European consensus of treatment of Crohn's disease]. Farmateka, 2008. no. 156, pp. 52-57. (In Russian).

Alban R. Evaluation of health-related quality of life in patient with inflammatory bowel disease. Intestinal disorders, 2008, no. 2-3, pp. 2-3.

Dorofeev A. E., Tudora A., Costantea C. Izmeneniya ekspressii MUC2, MUC3, MUC4, TFF3 v slizistoy obolochke tolstogo kishechnika u bolnyih nespetsificheskim yazvennyim kolitom [Expression change of MUC2, MUC3, MUC4, TFF3 in intestinal mucosa in patients with ulcerative colitis]. Gastroenterologiya, 2013, no. 1 (47), pp. 80 – 84. (In Russian).

Vasilenko I. V. Morfologicheskaya diagnostika nespetsificheskogo yazvennogo kolita [Morphological diagnosis of ulcerative colitis]. Novosti meditsinyi i farmatsii (gastroenterologiya), 2010, no. 313, pp. 23-28. (In Russian).

Belousova E. A., Nikitina N. V. Primeneniye aminosalitsilatov pri yazvennom kolite [The use of aminosalicylates in ulcerative colitis]. Klinitsist, 2008, no. 3, pp. 1-6. (In Russian).

Tkach S. M. Evolyutsiya vzglyadov na lecheniye vospalitelnyih zabolevaniy kishechnika [The evolution of views on the treatment of inflammatory bowel diseases]. Novosti meditsinyi i farmatsii, 2008, no. 251, pp. 54-57. (In Russian).

Shifrin O. S. Lekarstvennaya terapiya yazvennogo kolita i ee vozmozhnyie oslozhneniya [Drug therapy of ulcerative colitis and its possible complications]. Consilium Medicum, 2006, no. 6, pp. 27-29. (In Russian).

Doroshina M.G., Kutsenko M. G. Diagnosticheskiye i terapevticheskiye aspektyi bolezni Krona [Diagnostic and therapeutic aspects of Crohn's disease]. Byulleten meditsinskih internet konferentsiy. 2014, no. 4, pp. 386. (In Russian).

Sitkin S. I. Klinicheskaya effektivnost peroralnogo mesalazina i vyibor terapevticheskogo podhoda pri vospalitelnyih zabolevaniyah kishechnika [Clinical efficacy of oral mesalazine in the selection of therapeutic approach for inflammatory bowel disease]. Gastroenterologiya Sankt-Peterburga, 2009, no 4, pp. 2-6. (In Russian).

Abdulhakov S. R., Abdulhakov R. A. Nespetsificheskiy yazvennyiy kolit: sovremennyie podhodyi k diagnostike i lecheniyu [Ulcerative colitis: modern approaches to diagnostic and treatment] Vestnik sovremennoy klinicheskoy meditsinyi. 2009, no. 2 (1), pp. 32-41. (In Russian).

Atreya I., Neurath M. F. Azathioprine in inflammatory bowel disease: improved molecular insights and resulting clinical implications Expert. Rev. Gastroenterol. Hepatol, 2008, Vol. 2, no. 1, pp. 23-34.

Sandborn W. J., Feagan B. G., Stoinov S. Certolizumab pegol for the treatment of Crohn’s disease. Falk Gastro Review journal, 2008, no. 1, pp. 14-15.

Lee T. W., Kolber M. R., Fedorak R.N. Iron replacement therapy in inflammatory bowel disease patients with iron deficiency: a systematic review and meta-analysis. J Crohns colitis, 2013, no. 6(3), pp. 267-275.

Esters P., Dignass A. Complementary therapies in inflammatory bowel disease. Curr drug targets, 2015, no. 65, pp. 98-105.

Galeeva Z. M. Sovremennyie aspektyi lecheniya nespetsificheskogo yazvennogo kolita s tochki zreniya dokazatelnoy meditsinyi [Modern aspects of treatment of ulcerative colitis in terms of evidence-based medicine]. Vestn. sovr. klin. med., 2010, T. 3, no. 2, pp. 47 – 50. (In Russian).

Nosova I. A. Effektivnost primeneniya razlichnyih shem medikamentoznoy terapii pri nespetsificheskih vospalitelnyih zabolevaniyah kishechnika [The effectiveness of various schemes of medical treatment for inflammatory bowel disease]. Suchasna gastroenterologiya, 2007, no. 1 (33), pp. 28-30. (In Russian).

Targan S. R., Shanahan F., Karp L. C. Inflammatory Bowel Disease: From Bench to Bedside, 2nd ed. Kluwer Academic Publishers., Publ., 2003. 904 р.

Shevtsova Z. I., Boyko T. Y., Mosalova N. M. [Features of distribution and effectiveness of the treatment of diverticular bowel disease according to a retrospective analysis of medical records]. Trudy Mizhnarodnoi Naukovo-praktichnoi Konferentsiyi “Zabezpechennya zdorov’ya natsiyi ta zdorov’ya osobistosti yak prioritetna funktsiya derzhavi”.[Proc. Int. Conf. “Ensuring the health of the nation and the individual health as a priority function of the state”]. Odesa, 2015, pp. 79-80. (In Ukraian).

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 11 > >>